REGENXBIO Inc., founded in Washington D.C., is a biotechnology company dedicated to developing, commercializing, and licensing gene therapy solutions. Their core mission is to improve lives through the curative potential of gene therapy, leveraging their proprietary NAV® Technology Platform. REGENXBIO focuses on delivering one-time treatments for patients with common and rare diseases, aiming to usher in a new era of gene therapy innovation.
Notable affiliated individuals include scientific pioneers and industry leaders who have significantly contributed to the field of gene therapy. The company has attracted investment from prominent venture capital firms and strategic partners. Key achievements include advancing multiple gene therapy candidates into clinical trials and establishing collaborations with leading pharmaceutical companies. REGENXBIO's impact lies in its potential to transform treatment paradigms for various genetic disorders, offering hope for long-term cures.
